Using the hemoglobin content of reticulocytes (RET-He) to evaluate anemia in patients with cancer

American Journal of Clinical Pathology

Volumn 142, Issue 4, 2014, Pages 506-512

  Peerschke, Ellinor I B ^a,b   Pessin, Melissa S ^a   Maslak, Peter ^a,b  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

Anemia; Cancer; Hematology; Iron deficiency; RET He

Indexed keywords

FERRITIN; HEMOGLOBIN; IRON; TRANSFERRIN;

ADOLESCENT; ADULT; AGED; ARTICLE; CANCER PATIENT; CHILD; DIAGNOSTIC TEST ACCURACY STUDY; ERYTHROCYTE PARAMETERS; FALSE NEGATIVE RESULT; FEMALE; FERRITIN BLOOD LEVEL; HEMATOLOGIC MALIGNANCY; HEMATOPOIESIS; HUMAN; IRON BLOOD LEVEL; IRON DEFICIENCY ANEMIA; IRON THERAPY; MAJOR CLINICAL STUDY; MALE; MEAN CORPUSCULAR VOLUME; MEGALOCYTOSIS; PREDICTIVE VALUE; PRIORITY JOURNAL; REFERENCE VALUE; RETICULOCYTE COUNT; RETICULOCYTE HEMOGLOBIN CONTENT; SENSITIVITY AND SPECIFICITY; SOLID TUMOR; TRANSFERRIN SATURATION; ANEMIA, IRON-DEFICIENCY; BLOOD; COMPLICATION; INFANT; METABOLISM; MIDDLE AGED; NEOPLASM; PRESCHOOL CHILD; RETICULOCYTE; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; ANEMIA, IRON-DEFICIENCY; CHILD; CHILD, PRESCHOOL; ERYTHROCYTE INDICES; FEMALE; FERRITINS; HEMOGLOBINS; HUMANS; INFANT; IRON; MALE; MIDDLE AGED; NEOPLASMS; RETICULOCYTES; SENSITIVITY AND SPECIFICITY; TRANSFERRIN; YOUNG ADULT;

EID: 84921672199     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPCVZ5B0BOYJGN     Document Type: Article

References (51)

1. Brugnara C, Mohandas N. Red cell indices in classification and treatment of anemias: from M.M. Wintrobes's original 1934 classification to the third millennium. Curr Opin Hematol. 2013;20:222-230.
2. Brugnara C, Schiller B, Moran J. Reticulocyte hemoglobin equivalent (Ret He) and assessment of iron-deficient states. Clin Lab Haematol. 2006;28:303-308.
3. Buttarello M, Pajola R, Novello E, et al. Diagnosis of iron deficiency in patients undergoing hemodialysis. Am J Clin Pathol. 2010;133:949-954.
4. Garzia M, Di Mario A, Ferraro E, et al. Reticulocyte hemoglobin equivalent: an indicator of reduced iron availability in chronic kidney diseases during erythropoietin therapy. Lab Hematol. 2007;13:6-11.
5. Torsvik IK, Markestad T, Ueland PM, et al. Evaluating iron status and the risk of anemia in young infants using erythrocyte parameters. Pediatr Res. 2013;73:214-220.
6. Semmelrock MJ, Raggam RB, Amrein K, et al. Reticulocyte hemoglobin content allows early and reliable detection of functional iron deficiency in blood donors. Clin Chim Acta. 2012;413:678-682.
7. Joosten E, Lioen P, Brusselmans C, et al. Is analysis of the reticulocyte haemoglobin equivalent a useful test for the diagnosis of iron deficiency anaemia in geriatric patients? Eur J Int Med. 2013;24:63-66.
8. Karlsson T. Comparative evaluation of the reticulocyte hemoglobin content assay when screening for iron deficiency in elderly anemic patients. Anemia. 2011;2011:925907.
9. Schoorl M, Schoorl M, van der Gaag D, et al. Effects of iron supplementation on red blood cell hemoglobin content in pregnancy. Hematol Rep. 2012;4:e24.
10. Miwa N, Akiba T, Kimata N, et al. Usefulness of measuring reticulocyte hemoglobin equivalent in the management of haemodialysis patients with iron deficiency. Int J Lab Hematol. 2010;32:248-255.
11. Urrechaga E, Borque L, Escanero J F. Erythrocyte and reticulocyte indices in the assessment of erythropoiesis activity and iron availability. Int J Lab Hematol. 2013;35:144-149.
12. Brugnara C, Laufer MR, Friedman AJ, et al. Reticulocyte hemoglobin content (CHr): early indicator of iron deficiency and response to therapy. Blood. 1994;83:3100.
13. Major A, Mathez-Loic F, Rohling R, et al. The effect of intravenous iron on the reticulocyte response to recombinant human erythropoietin. Br J Haematol. 1997;98:292-294.
14. Chuang CL, Liu RS, Wei YH, et al. Early prediction of response to intravenous iron supplementation by reticulocyte haemoglobin content and high-fluorescence reticulocyte count in haemodialysis patients. Nephrol Dial Transplant. 2003;18:370-377.
15. Fishbane S, Galgano C, Langley RC Jr, et al. Reticulocyte hemoglobin content in the evaluation of iron status of hemodialysis patients. Kidney Int. 1997;52:217-222.
16. Fishbane S, Shapiro W, Dutka P, et al. A randomized trial of iron deficiency testing strategies in hemodialysis patients. Kidney Int. 2001;60:2406-2411.
17. Mittman N, Sreedhara R, Mushnick R, et al. Reticulocyte hemoglobin content predicts functional iron deficiency in hemodialysis patients receiving rHuEPO. Am J Kidney Dis. 1997;30:912-922.
18. Tsuchiya K, Okano H, Teramura M, et al. Content of reticulocyte hemoglobin is a reliable tool for determining iron deficiency in dialysis patients. Clin Nephrol. 2003;59:115-123.
19. Brittenham GM, Weiss G, Brissot P, et al. Clinical consequences of new insights in the pathophysiology of disorders of iron and heme metabolism. Am Soc Hemat Ed Prog. 2000;95:39-50.
20. Doig K. Disorders of iron metabolism. In: Rodak B, ed. Hematology: Clinical Principles and Applications. 2nd ed. Philadelphia, PA: Saunders; 2002.
21. Guyatt GH, Oxman AD, Ali M, et al. Laboratory diagnosis of iron-deficiency anemia: an overview. J Gen Intern Med. 1992;7:145-153.
22. Rehu M, Ahonen S, Punnonen K. The diagnostic accuracy of the percentage of hypochromic red blood cells (%HYPOm) and cellular hemoglobin in reticulocytes (CHr) in differentiating iron deficiency anemia and anemia of chronic diseases. Clin Chim Acta. 2011;412:1809-1813.
23. Canals C, Remacha A F, Sarda M P, et al. Clinical utility of the new Sysmex XE 2100 parameter-reticulocyte hemoglobin equivalent-in the diagnosis of anemia. Haematology. 2005;90:1133-1134.
24. Van Wyck DB, Alcorn H Jr, Gupta R. Analytical and biological variation in measures of anemia and iron status in patients treated with maintenance hemodialysis. Am J Kidney Dis. 2010;56:540-546.
25. Mast AE, Blinder MA, Dietzen DJ. Reticulocyte hemoglobin content. Am J Hematol. 2008;83:307-310.
26. Brugnara C, Zelmanovic D, Sorette M, et al. Reticulocyte hemoglobin: an integrated parameter for evaluation of erythropoietic activity. Am J Clin Pathol. 1997;108:133-142.
27. Brugnara C. Reticulocyte cellular indices: a new approach in the diagnosis of anemias and monitoring of erythropoietic function. Crit Rev Clin Lab Sci. 2000;37:93-130.
28. Brugnara C. Iron deficiency and erythropoiesis: new diagnostic approaches. Clin Chem. 2003;49:1573-1578.
29. Buttarello M, Temporin V, Ceravolo R, et al. The new reticulocyte parameter (RET-Y) of the Sysmex XE 2100: its use in the diagnosis and monitoring of posttreatment sideropenic anemia. Am J Clin Pathol. 2004;121:489-95.
30. Skarmoutsou C, Papassotiriou I, Traeger-Synodinos J, et al. Erythroid bone marrow activity and red cell hemoglobinization in iron sufficient beta-thalassemia heterozygotes as reflected by soluble transferrin receptor and reticulocyte hemoglobin in content: correlation with genotypes and Hb A(2) levels. Haematologica. 2003;88:631-636.
31. Mast AE, Blinder MA, Lu Q, et al. Clinical utility of the reticulocyte hemoglobin content in the diagnosis of iron deficiency. Blood. 2002;99:1489-1491.
32. Ervasti M, Kotisaari S, Heinonen S, et al. Use of advanced red blood cell and reticulocyte indices improves the accuracy in diagnosing iron deficiency in pregnant women at term. Eur J Haematol. 2007;79:539-545.
33. Alkhateeb AA, Connor JR. The significance of ferritin in cancer: anti-oxidation, inflammation and tumorigenesis. Biochim Biophys Acta. 2013;1836:245-254.
34. World Health Organization. Serum ferritin concentrations for the assessment of iron status and iron deficiency in populations. Vitamin and Mineral Nutrition Information System. 2011. www.who.int/vmnis/indicators/haemoglobin. pdf. Accessed October 2013.
35. Altman DG, Bland JM. Diagnostic tests 1: sensitivity and specificity. BMJ. 1994;308:1552.
36. Loong T W. Understanding sensitivity and specificity with the right side of the brain. BMJ. 2003;327:716-719.
37. Altman DG, Bland JM. Diagnostic tests 2: predictive values. BMJ. 1994;309:102.
38. Steinmetz HT. The role of intravenous iron in the treatment of anemia in cancer patients. Ther Adv Hematol. 2012;3:177-191.
39. Steinmetz HT, Tsamaloukas A, Schmitz S, et al. A new concept for the differential diagnosis and therapy of anaemia in cancer patients. Support Care Cancer. 2010;19:261-269.
40. Steinmetz T, Hellmich M, Neise M, et al. Prediction of the responsiveness to treatment with erythropoiesis-stimulating factors: a prospective clinical study in patients with solid tumors. Oncologist. 2007;12:748-755.
41. Glaspy J, Bukowski R, Steinberg D, et al. Impact of therapy with epoetin alfa on clinical outcomes in patients with nonmyeloid malignancies during cancer chemotherapy in community oncology practice. Procrit Study Group. J Clin Oncol. 1997;15:1218-1234.
42. Littlewood TJ, Bajetta E, Nortier J W, et al; Epoetin Alfa Study Group. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, doubleblind, placebo-controlled trial. J Clin Oncol. 2001;19:2865-2874.
43. Dangsuwan P, Manchana T. Blood transfusion reduction with intravenous iron in gynecologic cancer patients receiving chemotherapy. Gynecol Oncol. 2010;116:522-525.
44. Kim YT, Kim S W, Yoon BS, et al. Effect of intravenously administered iron sucrose on the prevention of anemia in the cervical cancer patients treated with concurrent chemoradiotherapy. Gynecol Oncol. 2007;105:199-204.
45. Rizzo JD, Brouwers M, Hurley P, et al. American Society of Hematology/American Society of Clinical Oncology clinical practice guideline update on the use of epoetin and darbepoetin in adult patients with cancer. Blood. 2010;116:4045-4059.
46. Holyoake TL, Stott DJ, McKay PJ, et al. Use of plasma ferritin concentration to diagnose iron deficiency in elderly patients. J Clin Pathol. 1993;46:857-860.
47. Leers M P, Keuren J F, Oosterhuis W P. The value of the Thomas-plot in the diagnostic work up of anemic patients referred by general practitioners. Int J Lab Hematol. 2010;32(6, pt 2):572-581.
48. Markovic M, Majkic-Singh N, Ignjatovic S, et al. Reticulocyte haemoglobin content vs. soluble transferrin receptor and ferritin index in iron deficiency anaemia accompanied with inflammation. Int J Lab Hematol. 2007;29:341-346.
49. Wong SS, Qutishat AS, Lange J, et al. Detection of iron-deficiency anemia in hospitalized patients by zinc protoporphyrin. Clin Chim Acta. 1996;244:91-101.
50. Bozkurt O, Berk V, Kaplan MA, et al. Lack of prognostic value of mean corpuscular volume with capecitabine therapy in metastatic breast cancer. Asian Pac J Cancer Prev. 2014;15:2501-2504.
51. Urrechaga E, Borque L, Escanero J F. Potential utility of the new Sysmex XE 5000 red blood cell extended parameters in the study of disorders of iron metabolism. Clin Chem Lab Med. 2009;47:1411-1416.